173459-53-5 Usage
Uses
Used in Pharmaceutical Industry:
1H-Indazole-1-carboxylic acid, 7-amino-, 1,1-dimethylethyl ester is used as a building block for the synthesis of pharmaceutical agents and drug candidates due to its chemical properties and potential to inhibit certain enzymes. Its role in the development of new medications is significant, as it can contribute to the creation of effective treatments for a range of diseases and conditions.
Used in Enzyme Inhibition Research:
In the field of enzyme inhibition, 1H-Indazole-1-carboxylic acid, 7-amino-, 1,1-dimethylethyl ester is utilized as a potential inhibitor of specific enzymes. Its capacity to interfere with enzymatic activity makes it a valuable compound for studying and potentially treating diseases where enzyme dysregulation plays a critical role.
Used in Laboratory Research:
1H-Indazole-1-carboxylic acid, 7-amino-, 1,1-dimethylethyl ester is also used in laboratory research settings for the exploration of its chemical properties and potential interactions with biological systems. Its application in research aids in understanding its mechanisms of action and helps in the advancement of pharmaceutical science and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 173459-53-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,3,4,5 and 9 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 173459-53:
(8*1)+(7*7)+(6*3)+(5*4)+(4*5)+(3*9)+(2*5)+(1*3)=155
155 % 10 = 5
So 173459-53-5 is a valid CAS Registry Number.
173459-53-5Relevant academic research and scientific papers
METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS
-
, (2008/06/13)
A method of inducing a Cholescystokinin-A receptor agonist response in a mammal by administering a compound of formula (I), STR1 where R 1 is C 1-C 6 alkyl, C 3-6 cycloalkyl, phenyl, or substituted phenyl; R 2 is C 3-6 alkyl, C 3-6 cycloalkyl, C 3-6 alkenyl, benzyl, phenylC 1-3 alkyl or substituted phenyl; or NR 1 R 2 together form 1,2,3,4-tetrahydroquinoline or benzazepine mono-, di-, or trisubstituted independently with C 1-6 alkyl, C 1-6 alkoxy or halogen substituents; n is an integer selected from the grouping consisting of 0, 1,2 or 3; p is the integer 0 or 1; q is the integer 0 or 1; r is the integer 0 or 1, provided that when q is 0 then r is 0; R 3, R 4, R 5 and R 8 are selected from a variety of substituents; X is nitrogen, nitroso or R 8 ; m is an integer selected from the group consisting of 0, 1, 2 or 3; Y and Z are hydrogen or halogen, novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).
